6562 logo

UBI Pharma Inc. Stock Price

TPEX:6562 Community·NT$1.7b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

6562 Share Price Performance

NT$0
0.00 (0.00%)
NT$0
0.00 (0.00%)
Price NT$0

6562 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Adequate balance sheet and slightly overvalued.

4 Risks
0 Rewards

UBI Pharma Inc. Key Details

NT$648.6m

Revenue

NT$451.5m

Cost of Revenue

NT$197.1m

Gross Profit

NT$196.3m

Other Expenses

NT$803.0k

Earnings

Last Reported Earnings
Dec 31, 2023
Next Reporting Earnings
n/a
0.0068
30.39%
0.12%
7.9%
View Full Analysis

About 6562

Founded
2014
Employees
n/a
CEO
Chei-Hsiang Chen
WebsiteView website
www.ubi-pharma.com

UBI Pharma Inc. develops, manufactures, and sells pharmaceutical products in Taiwan. The company offers protein drugs and formulations of molecule products; and develops biobetters and specialty injectables. Its product portfolio includes film coated, Virapine, and Efanzy tablets, as well as Terbutaline; and Levetir concentrate solution for infusion. The company was founded in 2014 and is based in Hsinchu City, Taiwan.

Recent 6562 News & Updates

Recent updates

No updates